Nuclear medicine therapy cures human non-Hodgkin’s lymphoma in preclinical model

A new nuclear medicine therapy can cure human non-Hodgkin’s lymphoma in an animal model, according to research published in the April issue of the Journal of Nuclear Medicine. A single dose of the radioimmunotherapy, [177Lu]Lu-ofatumumab, was found to quickly eliminate tumor cells and extend the life of mice injected with cancerous cells for more than 221 days (the trial endpoint), compared to fewer than 60 days for other treatments and just 19 days in untreated control mice.